Leerink Partners Downgrades Zentalis Pharmaceuticals (ZNTL) to Market Perform
Tweet
Share
E-mailGet Alerts ZNTL Hot Sheet
Price: $3.56 -14.22%
Rating Summary:
8 Buy, 6 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Rating Summary:
8 Buy, 6 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Join SI Premium – FREE
Leerink Partners analyst Andrew Berens downgraded Zentalis Pharmaceuticals (NASDAQ: ZNTL) from Outperform to Market Perform with a price target of $15.00 (from $37.00).
For an analyst ratings summary and ratings history on Zentalis Pharmaceuticals click here. For more ratings news on Zentalis Pharmaceuticals click here.
Shares of Zentalis Pharmaceuticals closed at $12.48 yesterday.
You May Also Be Interested In
- Fiserv (FISV) PT Lowered to $60 at Freedom Broker
- LG Electronics India (LGEL:IN) PT Raised to INR1,815 at ICICI Securities
- Chemtrade Logistics Income Fund (CHE-U:CN) (CGIFF) PT Raised to Cdn$18.50 at Desjardins
Create E-mail Alert Related Categories
Analyst PT Change, DowngradesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
